Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis

Modern Pathology

Volumn 19, Issue 8, 2006, Pages 1083-1090

  Ogino, Shuji ^a,b,c   Brahmandam, Mohan ^b   Kawasaki, Takako ^b   Kirkner, Gregory J ^a   Loda, Massimo ^a,b,c   Fuchs, Charles S ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adenoma; CIMP; Colon cancer; Epigenetics; Hypermethylation; MethyLight

Indexed keywords

B RAF KINASE; BINDING PROTEIN; CALCIUM CHANNEL; CALCIUM CHANNEL T TYPE; CELLULAR RETINOIC ACID BINDING PROTEIN 1; DNA; K RAS PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NEUROGENIN 1; PROTEIN; PROTEIN MLH1; PROTEIN P16INK4A; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

ADULT; AGED; ARTICLE; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; MICROSATELLITE INSTABILITY; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ADENOMA; AGED; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; GENE SILENCING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 33746277763     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800618     Document Type: Article

References (34)

1. Laird PW. Cancer epigenetics. Hum Mol Genet 2005; 14(Spec. no 1):R65-R76.
2. Kondo Y, Issa JP. Epigenetic changes in colorectal cancer. Cancer Metast Rev 2004;23:29-39.
3. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96:8681-8686.
4. Toyota M, Ohe-Toyota M, Ahuja N, et al. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci USA 2000;97:710-715.
5. van Rijnsoever M, Grieu F, Elsaleh H, et al. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 2002;51:797-802.
6. Hawkins N, Norrie M, Cheong K, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 2002;122:1376-1387.
7. Samowitz W, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005;129:837-845.
8. Ogino S, Cantor M, Kawasaki T, et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterized by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006: In press (published online first on January 11 2006: doi:10.1136/gut.2005.082933).
9. Ogino S, Kawasaki T, Brahmandam M, et al. Precision and performance characteristics of sodium bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006;8:209-217.
10. Eads CA, Danenberg KD, Kawakami K, et al. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase over-expression. Cancer Res 1999;59:2302-2306.
11. Eads CA, Danenberg KD, Kawakami K, et al. Methy-Light: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
12. Widschwendter M, Siegmund KD, Muller HM, et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004;64:3807-3813.
13. Zauber P, Sabbath-Solitare M, Marotta SP, et al. Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. Mol Pathol 2003;56:137-140.
14. Koness RJ, King TC, Schechter S, et al. Synchronous colon carcinomas: molecular-genetic evidence for multicentricity. Ann Surg Oncol 1996;3:136-143.
15. Eguchi K, Yao T, Konomoto T, et al. Discordance of p53 mutations of synchronous colorectal carcinomas. Mod Pathol 2000;13:131-139.
16. Lawes DA, Pearson T, Sengupta S, et al. The role of MLH1, MSH2 and MSH6 in the development of multiple colorectal cancers. Br J Cancer 2005;93:472-477.
17. Norrie MW, Hawkins NJ, Todd AV, et al. The role of hMLH1 methylation in the development of synchronous sporadic colorectal carcinomas. Dis Colon Rectum 2002;45:674-680.
18. Dykes SL, Qui H, Rothenberger DA, et al. Evidence of a preferred molecular pathway in patients with synchronous colorectal cancer. Cancer 2003;98:48-54.
19. Fuchs CS, Willett WC, Colditz GA, et al. The influence of folate and multivitamin use on the familial risk of colon cancer in women. Cancer Epidemiol Biomarkers Prev 2002;11:227-234.
20. Hamilton SR, Vogelstein B, Kudo S, et al. Carcinoma of the colon and rectum. Pathology and genetics of tumours of the digestive system. In: Aaltonen LA, Hamilton SR (eds). World Health Organization Classification of Tumours. IARC Press: Lyon, 2000, pp 103-119.
21. Eads CA, Lord RV, Wickramasinghe K, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001;61:3410-3418.
22. Eads CA, Lord RV, Kurumboor SK, et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 2000;60:5021-5026.
23. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005;7:413-421.
24. Ogino S, Brahmandam M, Cantor M, et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucious component. Mod Pathol 2006;19:59-68.
25. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-5257.
26. Ogino S, Meyerhardt JA, Cantor M, et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 2005;11:6650-6656.
27. Esteller M, Toyota M, Sanchez-Cespedes M, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000;60:2368-2371.
28. Esteller M, Risques RA, Toyota M, et al. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res 2001;61:4689-4692.
29. Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and the field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005;97:1330-1338.
30. Giovannucci E, Ogino S. DNA methylation, field effects, and colorectal cancer. J Natl Cancer Inst 2005; 97:1317-1319.
31. Yamashita K, Dai T, Dai Y, et al. Genetics supersedes epigenetics in colon cancer phenotype. Cancer Cell 2003;4:121-131.
32. Anacleto C, Leopoldino AM, Rossi B, et al. Colorectal cancer 'methylator phenotype': fact or artifact? Neoplasia 2005;7:331-335.
33. Chan AO-O, Issa J-PJ, Morris JS, et al. Concordant CpG island methylation in hyperplastic polyposis. Am J Pathol 2002;160:529-536.
34. Frigola J, Sole X, Paz MF, et al. Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer. Hum Mol Genet 2005;14:319-326.